1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Bioqual, Inc.

Bioqual, Inc.

BIOQ
Bioqual, Inc.US flagOther OTC
32.50
USD
- -
- -
29.07MMarket Cap
Bioqual, Inc.
BIOQ
(Other OTC)

Recent

price

32.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

1996
1997
1998
1999
2000
2001
2003
2004
2005
2006
2007
2010
2011
2017
2018
TTM
FRC
9.8
9.94
11.03
12.45
13.23
13.75
15.99
18.61
20.39
21.43
24.55
26.31
25.89
40.97
- -
26.56
Revenue per Share
0.1
0.01
-0.17
0.44
0.11
0.32
0.6
0.77
0.86
0.87
1.21
0.46
0.45
4.44
- -
0.76
Basic EPS, GAAP
0.45
-0.13
0.74
0.43
-0.13
0.96
0.9
-0.81
1.67
1.46
0.6
0.53
-0.2
5.21
- -
2.29
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.02
0.03
- -
- -
0.07
0.1
0.11
0.16
0.16
0.45
- -
- -
Dividend per Share
-3.85
-3.85
-4.1
-3.7
-3.65
-3.32
-2.21
-1.43
-0.53
0.33
1.43
4.22
4.53
14.14
- -
4.83
Book Value per Share
3.67
3.68
3.51
3.93
4.05
4.3
5.38
6.18
6.87
7.35
8.58
11.24
11.53
19.98
- -
11.83
Tangible Book Value per Share
1
1
1
1
1
1
1
1
1
1
1
1
1
1
- -
1
Basic Weighted Avg Shares
9
9
10
11
12
12
14
17
19
19
22
24
23
37
36
24
Sales/Revenue/Turnover
1.78
0.83
0.76
4.77
2.02
4.64
6.24
6.81
6.93
5.95
7.26
2.85
2.91
17.88
14.69
4.85
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
1
1
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
1
1
1
1
- -
- -
4
4
1
Net Income, GAAP
21.53
87.15
633.05
18.19
46.64
44.87
39.85
39.35
38.98
39.26
37.88
39.1
41.13
38.91
30.72
41.23
Effective Tax Rate (%)
1.05
0.05
-1.51
3.56
0.83
2.33
3.75
4.13
4.24
4.04
4.92
1.75
1.72
10.83
10.21
2.86
Profit Margin (%)
1
1
- -
1
1
1
2
2
3
3
4
7
8
15
17
8
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
3
3
3
3
4
4
5
6
6
7
8
10
10
19
22
11
Total Equity
- -
0.24
-10.35
11.45
2.96
7.14
11.79
12.97
12.73
10.62
13.67
4.6
3.87
26.69
17.48
6.52
Return on Invested Capital (%)
- -
-0.16
5.11
-12.93
-3.81
-11.92
-23.39
-46.25
-105.23
-834.14
136.78
16.36
10.18
46.38
25.31
16.69
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
136.78
16.36
10.18
47.45
25.8
16.69
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Feb'11
May'11
Aug'17
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
7
7
6

Working Capital

FRC

•

in mil. unless spec.
Feb'11
May'11
Aug'17
Total Current Assets
9
10
11
Cash, Cash Equivalents & STI
1
3
4
Accounts Receivable, Net
5
4
4
Inventories
- -
- -
- -
Total Current Liabilities
1
2
3
Payables & Accruals
1
2
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
1
2

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.61%
29.79%
16.57%
Free Cash Flow
-435.12%
-593.78%
-64.84%
Net Income, GAAP
117.43%
170.34%
-7.6%
Sales/Revenue/Turnover
12.87%
14.93%
-1.96%
Total Cash Common Dividend
- -
53.33%
33.33%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
No data availableFinancial data will appear here once available
Similar Companies
Danaher Corporation (DHR-PB)
Metropolis Healthcare Limited (METROPOLIS.BO)
BGI Genomics Co., Ltd. (300676.SZ)
Taihe Group, Inc. (TIHE)
Prostatype Genomics AB (publ) (PROGEN.ST)
Sona Nanotech Inc. (SNANF)
Business
BIOQUAL, Inc. provides contract research services focused on in vivo and in vitro preclinical testing for infectious diseases, cancer, and other human conditions to government agencies, primarily the National Institutes of Health, universities, and pharmaceutical companies in the United States; core offerings include animal models for HIV/SIV, Zika, dengue, influenza, RSV, hepatitis, malaria, and COVID-19; cell-based assays for proliferation, viability, apoptosis, and viral load; immunoassays such as ELISA, ELISpot, Luminex, Western blot, flow cytometry, quantitative PCR, virus neutralization, and hemagglutination inhibition; custom toxicology testing; high-throughput screening; BSL-3 biocontainment facilities; imaging services; custom animal model development; and GLP-compliant IND-enabling services encompassing pharmacokinetics and regulatory documentation. Founded in 1981 and headquartered in Rockville, Maryland, the company operates AAALAC-accredited facilities including vivariums at multiple locations in Rockville. Recent developments include a board change with the retirement of director Charles Francisco effective December 31, 2024; renewal or addition of operating leases recognizing new right-of-use assets of $7.4 million in fiscal 2025; and revenue mix shifts with commercial contracts comprising the majority amid a year-over-year decline to $48.9 million for the fiscal year ended May 31, 2025.

Company News

APIChatGPT

  • businesswire.com

    BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2026

  • defenseworld.net

    Reviewing Bioqual (OTCMKTS:BIOQ) and Option Care Health (NASDAQ:OPCH)

  • businesswire.com

    BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2026

  • defenseworld.net

    Financial Analysis: Encompass Health (NYSE:EHC) vs. Bioqual (OTCMKTS:BIOQ)

  • businesswire.com

    BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2026

  • businesswire.com

    BIOQUAL Presents Financial Results for Fiscal Year 2025

  • businesswire.com

    BIOQUAL Announces the retirement of Dr. Mark G. Lewis as President and CEO of the company

  • businesswire.com

    BIOQUAL Announces Retirement of Mike O'Flaherty From Board

  • businesswire.com

    BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2025

  • businesswire.com

    BIOQUAL Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2025

  • businesswire.com

    BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2025

  • businesswire.com

    BIOQUAL Declares Dividend

  • businesswire.com

    BIOQUAL Presents Financial Results for Fiscal Year 2024

  • businesswire.com

    BIOQUAL, Inc. Announces a Reduction in Workforce

  • businesswire.com

    BIOQUAL Presents Unaudited Financial Results for Third Quarter of Fiscal Year 2024

  • businesswire.com

    Bioqual Presents Unaudited Financial Results for Second Quarter of Fiscal Year 2024

  • businesswire.com

    BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2024

  • businesswire.com

    BIOQUAL Declares Dividend

  • businesswire.com

    BIOQUAL Presents Financial Results for Fiscal Year 2023